Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531242 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Not yet
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT03531242: Clinical Trial Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
NCT03531242 is a Phase 2 study that has not yet begun recruiting, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03531242, a Phase 2 study, has not yet begun recruiting, sponsored by U.S. Army Medical Research and Development Command.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.
Primary Outcome
The primary immunogenicity endpoint measurements will be the percentage of per-protocol subjects who develop titers of ≥ 1:20 as determined by PRNT80 after VEE vaccination at each scheduled time point for which blood samples are drawn and over the entire study period to study completion.
Interventions
- BIOLOGICAL 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-06 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What is known before NCT03531242 opens enrollment
NCT03531242 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).
The record links to 0 conditions, and to 1 intervention - of which 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 is the first listed.
NCT03531242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03531242 about?
NCT03531242 is a clinical study titled "Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults". The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.
What is the current status of trial NCT03531242?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2021-06. Estimated completion is 2024-12.
What interventions are being tested in trial NCT03531242?
The interventions under investigation include: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03531242?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03531242's enrollment target sits among peer trials
500 70th of 2000 higher than 1,927 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia